Skip to content
TrackPodcasts
newsMay 7, 20261:02:45pending

Regulating Compounding in the GLP-1 Era: A Conversatio | Essential: The Pharmacy Compounding Podcast

About this episode

This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those? Our deep dive is a special one: Our guest is Al Carter, the CEO of the National Association of Boards of Pharmacy, and he gives us a totally different perspective on the regulatory landscape at the level that affects pharmacists every day. Links from the podcast: The latest FDA statement on DTE: https://fllw.me/4sL6zXw  The Coalition for Compounding Excellence’s first audit process guide (compounding records and quality control): https://fllw.me/3Oew1qr  FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C  National Association of Boards of Pharmacy: https://nabp.pharmacy  Join APC! https://a4pc.org/join 

Get every episode summarized

Each time Pharmacy Podcast Network publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Regulating Compounding in the GLP-1 Era: A Conversatio | Essential: The Pharmacy Compounding Podcast

Pharmacy Podcast Network

0:00
1:02:45

More episodes

More from Pharmacy Podcast Network

View all episodes →